Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 29:29:15.
doi: 10.4103/jrms.jrms_452_22. eCollection 2024.

Predictors of gastrointestinal bleeding in patients with acute coronary syndrome and the optimal duration of dual antiplatelet therapy

Yanyu Wang  1 , Yingle Wu  1 , Jingqiao Wang  2 , Hengliang Zhang  1 , Laijing Du  1 , Ke Wang  1 , Hongqiang Duan  1
Affiliations

Predictors of gastrointestinal bleeding in patients with acute coronary syndrome and the optimal duration of dual antiplatelet therapy

Yanyu Wang et al. J Res Med Sci. .

Abstract

Background: This study aims to estimate the risk factors of gastrointestinal (GI) bleeding in patients with acute coronary syndrome (ACS) and to evaluate the optimal duration of dual antiplatelet therapy (DAPT).

Materials and methods: We enrolled 1266 patients with ACS in a telephone follow-up program to determine whether any of the patients were hospitalized for GI bleeding. We collected baseline data, laboratory tests, electrocardiograms, and echocardiography covering all ACS patients. Multivariable regression was performed to adjust for confounders and predictors of GI bleeding. At the same time, the optimal duration of DAPT for ACS patients was evaluated.

Results: A total of 1061 ACS patients were included in the study. After 13-68 months, 48 patients (4.5%) were hospitalized for GI bleeding. The risk of GI bleeding was significantly increased in patients treated with DAPT for more than 18 months (hazard ratio 12.792, 5.607-29.185, P < 0.01). Receiver Operating Characteristic curve showed that the duration of DAPT using a cutoff of 14.5 months resulted in a sensitivity of 66.7% and a specificity of 77%.

Conclusion: In patients with ACS, DAPT time are the main risk factors of GI bleeding. The optimal duration of DAPT is 14.5 months.

Keywords: Acute coronary syndrome; dual antiplatelet therapy; gastrointestinal bleeding.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Cumulative risk of gastrointestinal bleeding
Figure 2
Figure 2
The relation between duration of dual platelet therapy and risk of gastrointestinal bleeding
Figure 3
Figure 3
Receiver operating characteristic curve indicates the optimal duration of dual antiplatelet therapy. ROC = Receiver operating characteristic
See this image and copyright information in PMC

References

    1. Lau LH, Sung JJ. Treatment of upper gastrointestinal bleeding in 2020: New techniques and outcomes. Dig Endosc. 2021;33:83–94. - PubMed
    1. Pioppo L, Bhurwal A, Reja D, Tawadros A, Mutneja H, Goel A, et al. Incidence of non-variceal upper gastrointestinal bleeding worsens outcomes with acute coronary syndrome: Result of a national cohort. Dig Dis Sci. 2021;66:999–1008. - PubMed
    1. Pemmasani G, Elgendy I, Mamas MA, Leighton JA, Aronow WS, Tremaine WJ. Epidemiology and clinical outcomes of patients with inflammatory bowel disease presenting with acute coronary syndrome. Inflamm Bowel Dis. 2021;27:1017–25. - PubMed
    1. Hao Y, Liu J, Liu J, Smith SC, Jr., Huo Y, Fonarow GC, et al. Rationale and design of the improving care for cardiovascular disease in China (CCC) project: A national effort to prompt quality enhancement for acute coronary syndrome. Am Heart J. 2016;179:107–15. - PubMed
    1. Khan MY, Siddiqui WJ, Alvarez C, Aggarwal S, Hasni SF, Ahmad A, et al. Reduction in postpercutaneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet therapy: A systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018;30:847–53. - PubMed